Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $181.33

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus recommendation of “Buy” from the twenty-two ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, twenty have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $181.33.

SRPT has been the topic of several recent research reports. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Robert W. Baird decreased their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company.

Sarepta Therapeutics Stock Up 0.1 %

SRPT opened at $104.67 on Tuesday. The company has a 50 day moving average of $123.26 and a 200 day moving average of $132.19. The company has a market cap of $10.00 billion, a PE ratio of 83.74 and a beta of 0.81. Sarepta Therapeutics has a 12 month low of $78.67 and a 12 month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SRPT. Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at $31,000. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics in the 1st quarter worth about $32,000. Sunbelt Securities Inc. lifted its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank lifted its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares in the last quarter. Finally, Nkcfo LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth about $43,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.